

COLLEGE of AMERICAN PATHOLOGISTS

2019 MIPS Reporting: Which Path is Right for **Your Practice?**


Emily E. Volk, MD, MBA, FCAP

March 14, 2019



Emily E. Volk, MD, MBA, FCAP


- Vice Chair, Council on Government and Professional Affairs
- Chair of the Clinical Data Registry Ad-Hoc Committee



Today


- Quality Payment Program (QPP) and Merit-based Incentive **Payment System (MIPS)**
- Confirm your MIPS reporting status
- Determine your best reporting method by practice size
- Reporting on Quality Measures
- Attesting to Improvement Activities

Quality Payment Program Pathways




2019 MIPS Performance Year

- Quality Payment Measures: 85% of Final Score
- Improvement Activities: 15% of Final Score
- Minimum score: 30 points
 - If you do not score at least 30 points in 2019, you are subject to a penalty.
- **Exceptional performance bonus: 75 points**
 - Clinicians whose MIPS final score is 75 points or above are eligible to receive additional incentive 0 payments from a pool of \$500 million for exceptional performance.



© College of American Pathologists



IA

To Confirm Your 2019 MIPS Status

https://qpp.cms.gov/participation-lookup

Before you log on, have available:

- **HCQIS Access Roles and Profile System (HARP) credentials (formerly** 1. known as Enterprise Identity Data Management or EIDM)
- **Tax Identification Number (TIN)** 2.
- 3. **National Provider Identifier (NPI)**

SPECIAL STATUS	Yes
Hospital-based	
SPECIAL STATUS	Yes
Non-patient facing	
SPECIAL STATUS	Yes
Small practice	
Facility-based	Yes - UPMC HAMOT HOSPITAL

Low Volume Threshold Expansion + Opt-In

- Third Criterion Added to expand eligibility for low volume threshold:
 - To be excluded from MIPS, clinicians or groups would need to meet one of the 0 following three criteria:
 - ≤ \$90K in Part B allowed charges for covered professional services
 - Provide care to ≤ 200 beneficiaries •
 - Provide ≤ 200 covered professional services under the Physician Fee Schedule (PFS)
- New opt-in participation for low volume practices:
 - Starting in Year 3, clinicians or groups would be able to opt-in to MIPS if they meet or 0 exceed one or two, but not all, of the low-volume threshold criterion



Determine Your Best Reporting Method Based on Practice Size

	Small Practices (≤ 15 eligible pathologists)	Large Practices (16+ o pathologists)
Claims	Individual and/or group	NOT AVAILABLE
Qualified Registry (QR)	Individual and/or group	Individual and/or group
Qualified Clinical Data Registry (QCDR)	Individual and/or group	Individual and/or group

IMPORTANT UPDATE FOR 2019

Starting January 1, 2019, the claims/ your billing company submission mechanism can only be submitted by clinicians in a small practice (15 or fewer eligible clinicians), whether participating individually or as a group.

The claims/ your billing company submission mechanism is **NOT available** to clinicians in a practice of 16 or more eligible clinicians, whether participating as an individual or a group.



eligible	
)	
)	

2019 Quality Measure Changes

Extremely Topped-out Measures removed from MIPS:

- **Breast Cancer Resection Reporting** 0
- **Colon Cancer Resection Reporting** Ο
- **Quantitative IHC Evaluation of HER2 Testing in Breast Cancer Patients** 0
- Several Topped-out Measures assigned a 7-point cap benchmark

• The Pathologists Quality Registry updates:

- **21 QCDR measures added to the Registry** 0
- o 2 MIPS CQMs added
 - Biopsy Follow-up
 - Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time



Quality Category Requirements

- Report a minimum of 6 measures
 - One must be an outcome or high priority measure
- **OR** report on the complete Pathology Specialty Measure Set
- 12 month reporting period (January 1 December 31, 2019)
- 60% data completeness
- 20 case minimum per measure



10

Quality Measures Overview

• **QPP** Measures

- Medicare Part B Claims Measures and MIPS Clinical Quality Measures (MIPS CQMs)
 - MIPS CQMs were previously called Registry Measures
- Publicly available Ο
- **Comprise the 2019 Pathology Specialty Measure Set** 0
 - Specialty measure sets can be reported as an alternative to selecting 6 quality payment measures out of all possible quality payment measures
 - It is not a requirement for pathologists to report on the pathology specialty measure set; however, these are measures the majority of pathologists and/or groups should be able to report

Qualified Clinical Data Registry (QCDR) Measures

- Proprietary to QCDR
- Only reported through QCDR
- New measures added annually 0

Claims-Based Reporting: Small Practices Only

- Individual or group reporting
- Available only if you are in a small practice of 15 or fewer clinicians
- Will be subject to the Eligible **Measure Applicability (EMA)** process
 - Unless report on the Pathology **Specialty Measure Set**

Medicare Part B Claims Measures

QPP 249: Barrett Esophagus Pathology Reporting

QPP 250: Radical Prostatectomy Pathology Reporting

QPP 395: Lung Cancer Reporting (biopsy/cytology specimens)*

QPP 396: Lung Cancer Reporting (resection specimens)*

QPP 397: Melanoma Reporting*

*High-priority measure



Qualified Registry (QR) Reporting

- Seven MIPS Clinical Quality Measures (CQMs) available
 - Report on a minimum of six measures including an outcome or high priority measure
- Pathologists Quality Registry is a QR and a QCDR
- EMA applies if you report on less than six measures or do not report on an outcome/high priority measure

MIPS Clinical Quality Measures QPP 249: Barrett Esophagus Pathology Reporting QPP 250: Radical Prostatectomy Pathology Reporting **QPP 395: Lung Cancer Reporting (biopsy/cytology QPP 396: Lung Cancer Reporting (resection**

specimens)*

specimens)*

QPP 397: Melanoma Reporting*

QPP 265: Biopsy Follow-Up*

440: BCC/SCC Reporting*

*High-priority measure

Eligible Measure Applicability (EMA)

- If you report via claims or Qualified Registry and submit less than 6 quality measures or do not submit a high priority/outcome measure, CMS will determine whether additional measures should have been submitted
 - Applies to claims-based and QR reporting
 - Does not apply to QCDR reporting Ο
- If the CMS finds no additional applicable measures
 - Your quality score will be based on the measures submitted

Pathology Specialty Measure Set

- Clinicians and groups can choose to submit a specialty measure set
 - In doing so, they must submit data on at least 6 0 measures within that set; or if the set contains fewer than 6 measures, the clinician or group should submit each measure in the set
- 2019 is the first year the Pathology Measure Set contains < 6 measures
 - Can submit the 5 measures of the Pathology **Specialty Measure Set through the Qualified Registry or Medicare Part B Claims (small practices** only)

Patho	logy	Speci	alty
-------	------	-------	------

QPP 249: Barrett Esophagus Pathology Reporting

QPP 250: Radical Prostatectomy Pathology Reporting

QPP 395: Lung Cancer Reporting (biopsy/cytology specimens)*

QPP 396: Lung Cancer Reporting (resection specimens)*

QPP 397: Melanoma Reporting*

*High Priority Measures

Measure Set

Qualified Clinical Data Registry (QCDR) Reporting

- CAP's Pathologists Quality Registry
- One stop shopping
 - Allows individual or group reporting
 - Report on quality measures and/or improvement activities

More pathologist-specific measures to choose from

- Report on a minimum of six measures including an outcome or high priority \bigcirc measure
- EMA process does not apply to QCDRs so ensure you have at least six measures (including outcome/high priority) that you can report



16

QCDR Measures in Pathologists Quality Registry

Updated Measures for 2019

Turnaround Time (TAT) – Biopsies*

Cancer Protocol Elements and Turnaround Time for Carcinoma and Carcinosarcoma of the Endometrium*

Cancer Protocol Elements and Turnaround Time for Carcinoma of the Intrahepatic Bile Ducts*

Cancer Protocol Elements and Turnaround Time for Carcinoma of the Pancreas*

Cancer Protocol Elements and Turnaround Time for Carcinoma of the Pancreas*

Cancer Protocol Elements and Turnaround Time for Invasive Carcinoma of Renal Tubular Origin*

Helicobacter pylori Status and Turnaround Time*

Measures with no Changes for 2019

Turnaround Time (TAT) – Troponin*

Turnaround Time (TAT) – Lactate*

*High Priority Measures

New Measures for 2019

HER2 Tumor Evaluation and Repeat Evaluation in Patients with Breast Carcinoma*

HER2 Tumor Evaluation and Repeat Evaluation in Patients with Gastroesophageal Adenocarcinoma*

Appropriate Formalin Fixation Time (6 – 72 hours) of **Breast Cancer Specimens**

Blood Laboratory Samples for Potassium Determination with Hemolysis Drawn in the Emergency Department**

EGFR Testing in Patients with NSCLC*

ROS 1 Testing in Patients with NSCLC*

ALK Testing to in Patients with NSCLC*

BRAF Testing in Patients with Metastatic Colorectal Adenocarcinoma*

MMR or MSI Testing in Patients with Primary or Metastatic **Colorectal Carcinoma***

FLT3-ITD Testing to in Patients with Acute Myeloid Leukemia*

High Risk HPV Testing and p16 Scoring in Surgical **Specimens for Patients with OPSCC***

High Risk HPV Testing in Cytopathology Specimens for Patients with OPSCC*



Pathologists Quality Registry: Quality Measures

Pathologists Can Review Performance on Each Measure and Drill Down to Detail on Each Case

SJONES@CAP.ORG	PATH Advoca	EGE of AMERICAN IOLOGISTS cy logists Quality Registry							
) Data Entry Tool 🛛 😌 M	IPS> Practic	e > Web Demo Practice >	Quality	Practice ID: 6 Practice Name: Web	Demo Practice				
MIPS 😑	Quality	IA Suii	iiiiai y						
Pathologist	CMS Rec	commendations: ✔ 6	measures 🗸	1 Outcome/High priority measure 🖌 20 cases per measure	ALL	\supset			
actice	Submiss	ion Type: QR 🔻	Dur	ration: Q1 + Q2 + Q3 + Q4 •	AVE				
out	CMS would	d score MIPS eligible path	ologists on the	all-cause hospital readmission measure for groups of 16 or more if t	he group has sufficient case volume	e (200 cases) a	and the total	l possible poir	nts for the quality performance catego
	Perfor	mance score: 34.3 🚯	Bon	us points: 4 (1) Quality score: 38.3/60 (1)	Contribution to	MIPS: 54.26/8	35 🚯		CMS Score: 😌
	🍽 Denote	s best preferred measure	for submission	 Null performance- all denominators under exclusion or exception. 	P Denotes zero performance mea	isure.)	Denotes de	efault performance measure.
	2	QUALITY ID 🔶	QPP ID \$	MEASURE \$	MEASURE TYPE 💠 DEN 🗧	NUM \$	EXCL \$	EXCPT \$	MEASURE PERFORMANCE
		QPP 99	099	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Process 27	27	0	0	(Registry Average: 84.83%)
		QPP 100	100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Process 25	24	0	0	(Registry Average: 86.57%)
		QPP 249	249	Barrett's Esophagus DETAILS	Process 21	20	0	1	(Registry Average: 90.07%)
		QPP 250	250	Radical Prostatectomy Pathology Reporting DETAILS	Process 8	5	0	0	(Registry Average: 83.51%)
		QPP 251	251	Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	Structure 2	1	0	0	(Registry Average: 92.68%)
© 2018	Image: Second	QPP 395 🛛	395	Lung Cancer Reporting (Biopsy/Cytology Specimens)	Outcome 25	20	4	0	(Penistry Average: 72 66%)





Improvement Activity Attestation

- Attest to 1 high-weighted or 2 mediumweighted Improvement Activities (IAs) if you are a non-patient-facing pathologist
- Perform the activity for a minimum of 90 consecutive days
- If reporting for quality measures as individuals, must individually attest to IAs



18 Pathologyspecific activities (available on cap.org/advocacy)

Pathologists Quality Registry: Improvement Activities


Easier for Pathologists to Make Sense of and Attest to Improvement Activities

	COLLEGE of AMERIC PATHOLOGISTS Advocacy Pathologists Quality Reg							
	MIPS> Practice > Web Demo Prac	ctice > IA	Practice ID	0: 6 Practice Name: W	eb Demo Practice			
MIPS	MIPS ELIGIBILITY	TIN		TIN VALID FROM	TIN VALID TO	DRCF SUBMISSION STATU	S ESTIMATED MIPS TOTAL SCORE	CMS MIPS SCORE
Pathologist Practice	Eligible	987654321	v 🕑	01-01-20	12-31-2017	Pending Pending	69.26	; NA
Contact & Support	Quality IA	Summary						
Logout	From: 01-01-2017	To: 12-31-2017		ivate payer, or other body		nparable Specialty Practice that has red medical home accreditation and		
	✓ 2 Activities selected		IA score: 40		Contribu	tion to MIPS: 15/15 🔕	CMS Score: 😏	
	Each activity must be perform	ned for 90 consecutive days to g	get any points.					
	SELECT ONE OR MOR	E SUBCATEGORIES					🔲 cehrt activity 🔳 high wei	ght activity 📕 Your Favor
	 Registry Suggested Act Expanded Practice Act Population Manageme Care Coordination 	cess			of QCDR to support clinical decis			20 ☆ 20 ☆
	Care Coordination Beneficiary Engagement Patient Safety and Practice Assessment				· ·	ute to more timely communication of test		20 🏠
	Patient Safety and Pra	ctice Assessment		able communication of text rea	ults defined as timely identification	of abnormal test results with timely follo	w-up	
	 Patient Safety and Pra Achieving Health Equit Emergency Response Behavioral and Mental 	ty and Preparedness	Tin	Activity ID IA_CC_2 Activity Weig Medium	·	Subcat	egory Name ordination	
	 Achieving Health Equit Emergency Response 	ty and Preparedness		Activity ID IA_CC_2 Activity Weig Medium	hting	Subcat	ordination	20 😭



Pathologists Quality Registry: MIPS Dashboard

Enhance practice success and levels of patient care via registry dashboards and quarterly benchmarking reports providing feedback on individual and/or pathology practice performance





no Practice			
CMS MIPS SCORE			
	NA	۵	
CONTRIBUTION TO MIPS			
54.26			
15			
69.26			
NA			

The CAP Has MIPS Resources

- Visit cap.org/advocacy for MIPS tools and resources
- 2019 Updates Coming Soon
 - Making Sense of CMS's Quality Payment Program (Video)
 - MIPS Checklist for Pathologists
 - MIPS FAQs
 - MIPS Financial Impact Calculator
 - Understanding Your MIPS Reporting Options
 - Pathology-specific Quality Measures
 - 2019 Improvement Activities for Pathologists

• Read STATLINE

22

Questions?

Email us at MIPS@cap.org

© College of American Pathologists.

23

